Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients With Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The American Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran
Am J Med 2021 Nov 30;[EPub Ahead of Print], A Holt, JE Strange, PV Rasmussen, P Blanche, N Nouhravesh, MH Jensen, AM Schjerning, M Schou, C Torp-Pedersen, GH Gislason, ML Hansen, P McGettigan, M LambertsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.